Cite
HARVARD Citation
Nastoupil, L. et al. (2017). High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. British journal of haematology. pp. 263-270. [Online].